Wedbush Reaffirms “Outperform” Rating for Bicara Therapeutics (NASDAQ:BCAX)

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research report issued on Tuesday,Benzinga reports. They currently have a $30.00 price objective on the stock. Wedbush’s target price suggests a potential upside of 46.34% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Citizens Jmp restated a “market outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a report on Tuesday. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Bank of America started coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price target on the stock. Mizuho raised Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Bicara Therapeutics Stock Up 3.1%

Shares of BCAX stock opened at $20.50 on Tuesday. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $21.05. The company’s fifty day simple moving average is $17.28 and its 200-day simple moving average is $16.69. The firm has a market cap of $1.34 billion, a PE ratio of -8.10 and a beta of -1.24.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. On average, equities analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Claire Mazumdar sold 1,596 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $18.95, for a total value of $30,244.20. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,431,478.40. This trade represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $19.66, for a total value of $245,750.00. Following the transaction, the chief operating officer owned 200,641 shares of the company’s stock, valued at $3,944,602.06. This represents a 5.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 137,969 shares of company stock worth $2,586,198 over the last ninety days. 15.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in shares of Bicara Therapeutics in the first quarter valued at about $248,000. Woodline Partners LP boosted its holdings in shares of Bicara Therapeutics by 26.5% during the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after buying an additional 72,998 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Bicara Therapeutics by 36.8% during the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after buying an additional 180,833 shares during the period. Intech Investment Management LLC grew its stake in Bicara Therapeutics by 65.3% in the 2nd quarter. Intech Investment Management LLC now owns 27,673 shares of the company’s stock valued at $257,000 after buying an additional 10,927 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Bicara Therapeutics by 26.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after buying an additional 5,664 shares during the last quarter.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Wall Street analyst consensus implies a large upside (~54.9%) to BCAX based on average price targets and improving earnings-estimate revisions, a factor traders cite as justification for buying interest. Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here’s is How to Trade
• Positive Sentiment: Clinical progress: Seeking Alpha reiterates a Buy rating as BCAX advances its pivotal phase 3 FORTIFI-HN01 study; strong phase 1/1b signals (12‑month OS 61%, ORR 54% with ficerafusp alfa + KEYTRUDA) support the program. Key upcoming catalysts: phase‑3 interim readout mid‑2027 and long‑term phase 1b follow‑up at ASCO 2026. Near‑full enrollment expected by year‑end. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 / cash position: Earnings call highlights show a stronger cash position and a slight beat on Q4 EPS vs. estimates, which reduces near‑term dilution risk and supports runway for clinical execution. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript is available for investors digging into management comments on timelines and cash burn; useful for detailed diligence but not a single price driver by itself. Q4 2025 earnings call transcript
• Negative Sentiment: Mixed analyst views: Goldman Sachs raised its PT to $16 (neutral) and Wells Fargo to $16 (equal‑weight)—both targets sit well below the current market price, implying downside from their perspective. These conservative calls can cap near‑term upside and add volatility. Benzinga coverage of analyst moves
• Positive Sentiment: Other broker support remains bullish: Wedbush (outperform, $30 PT), Citizens Jmp (market outperform, $31 PT) and HC Wainwright (buy, PT $42) provide higher upside scenarios that likely underlie investor optimism. Benzinga coverage of analyst moves

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.